Shopping Cart 0
Cart Subtotal
USD 0

Oncolytics Biotech Inc (ONC) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company's lead product, Reolysin, a formulation of the human reovirus, is indicated for the treatment of lung, ovarian, colorectal, pancreatic, prostate, breast, head and neck cancers. Reolysin is also undergoing various other clinical trials to determine its use in other types of cancer, such as for squamous cell carcinoma, metastatic colorectal cancer, metastatic melanoma trial, and non-small cell lung cancer. The company and its partners conduct clinical trials across Canada and the US. Oncolytics is headquartered in Calgary, Alberta, Canada.

Oncolytics Biotech Inc (ONC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 13

Private Equity 13

Oncolytics Biotech to Raise up to USD26 Million in Private Placement of Shares 13

Partnerships 14

Oncolytics Biotech Enters into Agreement with SOLTI 14

Oncolytics Biotech Enters into Research Partnership with Keck School of Medicine of University of Southern California 15

Licensing Agreements 16

Oncolytics Biotech Enters into Licensing Agreement with Adlai Nortye Biopharma 16

Equity Offering 17

Oncolytics Biotech Raises USD8.9 Million in Public Offering of Share 17

Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 18

Oncolytics Biotech to Raise USD20 Million in Public Offering of Common Stock 19

Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For USD 1 Million 20

Oncolytics Biotech Completes Public Offering Of Common Stock For USD 32 Million 21

Oncolytics Biotech Completes Private Placement Of Shares For USD 21 Million 22

Oncolytics Biotech Inc-Key Competitors 24

Oncolytics Biotech Inc-Key Employees 25

Oncolytics Biotech Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Strategy And Business Planning 27

Jun 27, 2017: Oncolytics Biotech Opens U.S. Based Office in San Diego 27

Financial Announcements 28

Aug 03, 2018: Oncolytics Biotech reports 2018 second quarter results 28

May 11, 2018: Oncolytics Biotech Reports 2018 First Quarter Results 29

Mar 09, 2018: Oncolytics Biotech Announces 2017 Year End Results 30

Nov 08, 2017: Oncolytics Biotech Announces 2017 Third Quarter Results 32

Aug 03, 2017: Oncolytics Biotech Announces 2017 Second Quarter Results 33

May 05, 2017: Oncolytics Biotech Announces 2017 First Quarter Results 34

Mar 10, 2017: Oncolytics Biotech Announces 2016 Year-End Results 35

Corporate Communications 36

Jun 01, 2018: Oncolytics Biotech Announces Listing on Nasdaq Capital Market 36

May 29, 2018: Oncolytics Biotech Announces New OTCQX Ticker Symbol 37

Apr 17, 2018: Oncolytics Biotech Announces Resignation Of Andres Gutierrez As Chief Medical Officer 38

Jun 29, 2017: Oncolytics Biotech Appoints Andrew de Guttadauro, President of Oncolytics Biotech 39

Jan 19, 2017: Oncolytics Biotech Appoints Dr. Matt Coffey to the Role of President and CEO 40

Product News 41

12/27/2017: Oncolytics Biotech Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 41

11/30/2017: Oncolytics Biotech Establishes Scientific Advisory Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer 42

11/02/2017: Oncolytics Biotech Appoints Deborah Brown to Board of Directors 43

10/02/2018: Oncolytics Biotech announces a publication demonstrating that intravenously delivered oncolytic viruses effectively target tumors even in the presence of neutralizing antibodies 44

09/19/2018: Oncolytics Biotech provides corporate and clinical update 45

09/19/2017: Oncolytics Biotech to Present at the Phacilitate Immuno-Oncology Frontiers Conference 46

09/17/2018: Oncolytics Biotech announces investigator sponsored multiple myeloma study combining REOLYSIN and Nivolumab (Opdivo) with standard of care 47

06/04/2018: Oncolytics Biotech Announces Poster Presentation Demonstrating the Ability of REOLYSIN to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting 48

05/23/2017: Oncolytics Biotech Announces Participation in World Immunotherapy Congress USA 2017 49

05/16/2018: Oncolytics Biotech Announces Publication of REOLYSIN Abstract for the ASCO 2018 Annual Meeting 50

04/18/2018: Oncolytics Biotech Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018 51

04/10/2018: Oncolytics Biotech Presents Positive REOLYSIN Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018 52

04/04/2018: Oncolytics Biotech to Present at the MicroCap Conference 53

03/20/2018: Oncolytics Biotech Scientist Selected to Participate in the Society of Immunotherapy of Cancers METIOR Incubator Program 54

03/14/2018: Oncolytics Biotech Announces Publication of REOLYSIN Abstract for the AACR 2018 Annual Meeting 55

02/27/2018: Oncolytics Biotech to Present REOLYSIN at the 2018 Precision: Breast Cancer World R&D Summit 56

01/16/2018: Oncolytics Biotech Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 57

Product Approvals 58

Dec 05, 2017: Oncolytics Biotech Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN in Metastatic Breast Cancer 58

May 08, 2017: Oncolytics Biotech Announces FDA Fast Track Designation for REOLYSIN in Metastatic Breast Cancer 59

Clinical Trials 60

Oct 11, 2018: Oncolytics Biotech announces publication of positive clinical results for Pelareorep in abstract for ESMO 2018 Congress 60

May 17, 2018: Oncolytics Biotech Announces Collaboration with Merck and Northwestern University Combining Keytruda and REOLYSIN in a Phase 2 Second Line Pancreatic Cancer Study 61

May 10, 2018: Oncolytics Biotech Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer 62

Feb 01, 2018: Oncolytics Biotech to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN 63

Jan 19, 2018: Oncolytics Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 64

Dec 04, 2017: Oncolytics Biotech to Present at the Oncolytic Virotherapy Summit 65

Oct 11, 2017: Oncolytics Biotech to Present at the 2017 BIO Investor Forum 66

Sep 18, 2017: Oncolytics Biotech Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN in Metastatic Breast Cancer 67

Sep 14, 2017: Oncolytics Biotech Announces First Patient Treated in MUK eleven Study 68

Sep 11, 2017: Oncolytics Biotech Announces the Presentation of REOLYSIN Clinical Data at ESMO 2017 Congress 69

Jul 26, 2017: Oncolytics Biotech to Present REOLYSIN Safety Data in Combination with Chemotherapy at ESMO 2017 Congress 70

May 17, 2017: Oncolytics Biotech Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers 71

Apr 27, 2017: Oncolytics Biotech Announces Details of 2017 Annual Meeting of Shareholders 72

Apr 12, 2017: Oncolytics Biotech Announces Registration Pathway and Clinical Development Plan 73

Apr 05, 2017: Oncolytics Biotech's REOLYSIN More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer 75

Mar 31, 2017: Oncolytics Biotech REOLYSIN Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer 76

Mar 16, 2017: Myeloma UK launches world-first novel immunotherapy trial 77

Mar 02, 2017: Oncolytics Biotech Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting 78

Other Significant Developments 79

Sep 13, 2018: Viruses show new promise in treating cancer 79

Mar 08, 2018: Oncolytics Biotech Chief Medical Officer to Facilitate Roundtable Discussion at the US Immuno-Oncology Strategy Meeting 81

Appendix 82

Methodology 82

About GlobalData 82

Contact Us 82

Disclaimer 82


List Of Figure

List of Figures

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Oncolytics Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Oncolytics Biotech to Raise up to USD26 Million in Private Placement of Shares 13

Oncolytics Biotech Enters into Agreement with SOLTI 14

Oncolytics Biotech Enters into Research Partnership with Keck School of Medicine of University of Southern California 15

Oncolytics Biotech Enters into Licensing Agreement with Adlai Nortye Biopharma 16

Oncolytics Biotech Raises USD8.9 Million in Public Offering of Share 17

Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 18

Oncolytics Biotech to Raise USD20 Million in Public Offering of Common Stock 19

Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For USD 1 Million 20

Oncolytics Biotech Completes Public Offering Of Common Stock For USD 32 Million 21

Oncolytics Biotech Completes Private Placement Of Shares For USD 21 Million 22

Oncolytics Biotech Inc, Key Competitors 24

Oncolytics Biotech Inc, Key Employees 25

Oncolytics Biotech Inc, Other Locations 26

Oncolytics Biotech Inc, Subsidiaries 26

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Oncolytics Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Oncolytics Biotech Inc (Oncolytics) is a development stage biopharmaceutical company which focuses on the discovery and development of oncolytic viruses for the treatment of cancer. The company's lead product, Reolysin, a formulation of the human reovirus, is indicated for the treatment of lung, ovarian, colorectal, pancreatic, prostate, breast, head and neck cancers. Reolysin is also undergoing various other clinical trials to determine its use in other types of cancer, such as for squamous cell carcinoma, metastatic colorectal cancer, metastatic melanoma trial, and non-small cell lung cancer. The company and its partners conduct clinical trials across Canada and the US. Oncolytics is headquartered in Calgary, Alberta, Canada.

Oncolytics Biotech Inc (ONC)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 6

List of Figures 6

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deal Details 13

Private Equity 13

Oncolytics Biotech to Raise up to USD26 Million in Private Placement of Shares 13

Partnerships 14

Oncolytics Biotech Enters into Agreement with SOLTI 14

Oncolytics Biotech Enters into Research Partnership with Keck School of Medicine of University of Southern California 15

Licensing Agreements 16

Oncolytics Biotech Enters into Licensing Agreement with Adlai Nortye Biopharma 16

Equity Offering 17

Oncolytics Biotech Raises USD8.9 Million in Public Offering of Share 17

Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 18

Oncolytics Biotech to Raise USD20 Million in Public Offering of Common Stock 19

Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For USD 1 Million 20

Oncolytics Biotech Completes Public Offering Of Common Stock For USD 32 Million 21

Oncolytics Biotech Completes Private Placement Of Shares For USD 21 Million 22

Oncolytics Biotech Inc-Key Competitors 24

Oncolytics Biotech Inc-Key Employees 25

Oncolytics Biotech Inc-Locations And Subsidiaries 26

Head Office 26

Other Locations & Subsidiaries 26

Recent Developments 27

Strategy And Business Planning 27

Jun 27, 2017: Oncolytics Biotech Opens U.S. Based Office in San Diego 27

Financial Announcements 28

Aug 03, 2018: Oncolytics Biotech reports 2018 second quarter results 28

May 11, 2018: Oncolytics Biotech Reports 2018 First Quarter Results 29

Mar 09, 2018: Oncolytics Biotech Announces 2017 Year End Results 30

Nov 08, 2017: Oncolytics Biotech Announces 2017 Third Quarter Results 32

Aug 03, 2017: Oncolytics Biotech Announces 2017 Second Quarter Results 33

May 05, 2017: Oncolytics Biotech Announces 2017 First Quarter Results 34

Mar 10, 2017: Oncolytics Biotech Announces 2016 Year-End Results 35

Corporate Communications 36

Jun 01, 2018: Oncolytics Biotech Announces Listing on Nasdaq Capital Market 36

May 29, 2018: Oncolytics Biotech Announces New OTCQX Ticker Symbol 37

Apr 17, 2018: Oncolytics Biotech Announces Resignation Of Andres Gutierrez As Chief Medical Officer 38

Jun 29, 2017: Oncolytics Biotech Appoints Andrew de Guttadauro, President of Oncolytics Biotech 39

Jan 19, 2017: Oncolytics Biotech Appoints Dr. Matt Coffey to the Role of President and CEO 40

Product News 41

12/27/2017: Oncolytics Biotech Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 41

11/30/2017: Oncolytics Biotech Establishes Scientific Advisory Board Focused on REOLYSIN Registration Study in Metastatic Breast Cancer 42

11/02/2017: Oncolytics Biotech Appoints Deborah Brown to Board of Directors 43

10/02/2018: Oncolytics Biotech announces a publication demonstrating that intravenously delivered oncolytic viruses effectively target tumors even in the presence of neutralizing antibodies 44

09/19/2018: Oncolytics Biotech provides corporate and clinical update 45

09/19/2017: Oncolytics Biotech to Present at the Phacilitate Immuno-Oncology Frontiers Conference 46

09/17/2018: Oncolytics Biotech announces investigator sponsored multiple myeloma study combining REOLYSIN and Nivolumab (Opdivo) with standard of care 47

06/04/2018: Oncolytics Biotech Announces Poster Presentation Demonstrating the Ability of REOLYSIN to Promote and Predict Response to Checkpoint Inhibitors at ASCO 2018 Annual Meeting 48

05/23/2017: Oncolytics Biotech Announces Participation in World Immunotherapy Congress USA 2017 49

05/16/2018: Oncolytics Biotech Announces Publication of REOLYSIN Abstract for the ASCO 2018 Annual Meeting 50

04/18/2018: Oncolytics Biotech Demonstrates Positive Data in Two Posters at AACR Annual Meeting 2018 51

04/10/2018: Oncolytics Biotech Presents Positive REOLYSIN Data in Combination with Keytruda and anti-CD73 at International Oncolytic Virus Conference 2018 52

04/04/2018: Oncolytics Biotech to Present at the MicroCap Conference 53

03/20/2018: Oncolytics Biotech Scientist Selected to Participate in the Society of Immunotherapy of Cancers METIOR Incubator Program 54

03/14/2018: Oncolytics Biotech Announces Publication of REOLYSIN Abstract for the AACR 2018 Annual Meeting 55

02/27/2018: Oncolytics Biotech to Present REOLYSIN at the 2018 Precision: Breast Cancer World R&D Summit 56

01/16/2018: Oncolytics Biotech Announces Abstract for Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 57

Product Approvals 58

Dec 05, 2017: Oncolytics Biotech Receives Favorable Final Advice Letter from the European Medicines Agency for REOLYSIN in Metastatic Breast Cancer 58

May 08, 2017: Oncolytics Biotech Announces FDA Fast Track Designation for REOLYSIN in Metastatic Breast Cancer 59

Clinical Trials 60

Oct 11, 2018: Oncolytics Biotech announces publication of positive clinical results for Pelareorep in abstract for ESMO 2018 Congress 60

May 17, 2018: Oncolytics Biotech Announces Collaboration with Merck and Northwestern University Combining Keytruda and REOLYSIN in a Phase 2 Second Line Pancreatic Cancer Study 61

May 10, 2018: Oncolytics Biotech Receives Special Protocol Assessment Agreement from FDA for Phase 3 Clinical Trial of Pelareorep In Metastatic Breast Cancer 62

Feb 01, 2018: Oncolytics Biotech to Host Conference Call Outlining the Treatment Paradigm of Metastatic Breast Cancer Subtypes and Provide Topline Information on its Phase 3 Registration Study with REOLYSIN 63

Jan 19, 2018: Oncolytics Announces Poster Presentation at the 2018 Gastrointestinal Cancers Symposium Sponsored by ASCO in Patients with Relapsed Metastatic Adenocarcinoma of the Pancreas 64

Dec 04, 2017: Oncolytics Biotech to Present at the Oncolytic Virotherapy Summit 65

Oct 11, 2017: Oncolytics Biotech to Present at the 2017 BIO Investor Forum 66

Sep 18, 2017: Oncolytics Biotech Announces Successful End-of-Phase 2 Meeting with FDA for REOLYSIN in Metastatic Breast Cancer 67

Sep 14, 2017: Oncolytics Biotech Announces First Patient Treated in MUK eleven Study 68

Sep 11, 2017: Oncolytics Biotech Announces the Presentation of REOLYSIN Clinical Data at ESMO 2017 Congress 69

Jul 26, 2017: Oncolytics Biotech to Present REOLYSIN Safety Data in Combination with Chemotherapy at ESMO 2017 Congress 70

May 17, 2017: Oncolytics Biotech Announces ASCO Abstracts and Preliminary Data for Studies in Pancreatic and Prostate Cancers 71

Apr 27, 2017: Oncolytics Biotech Announces Details of 2017 Annual Meeting of Shareholders 72

Apr 12, 2017: Oncolytics Biotech Announces Registration Pathway and Clinical Development Plan 73

Apr 05, 2017: Oncolytics Biotech's REOLYSIN More than Doubles Overall Survival in Patients with Mutated p53 Metastatic Breast Cancer 75

Mar 31, 2017: Oncolytics Biotech REOLYSIN Provides Statistically Significant Improvement in Overall Survival in Canadian Cancer Trials Group Sponsored Randomized Phase 2 Study in Metastatic Breast Cancer 76

Mar 16, 2017: Myeloma UK launches world-first novel immunotherapy trial 77

Mar 02, 2017: Oncolytics Biotech Announces Canadian Cancer Trials Group to Present Final Randomized Data from Phase 2 Metastatic Breast Cancer Study at AACR 2017 Annual Meeting 78

Other Significant Developments 79

Sep 13, 2018: Viruses show new promise in treating cancer 79

Mar 08, 2018: Oncolytics Biotech Chief Medical Officer to Facilitate Roundtable Discussion at the US Immuno-Oncology Strategy Meeting 81

Appendix 82

Methodology 82

About GlobalData 82

Contact Us 82

Disclaimer 82


List Of Figure

List of Figures

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11


List Of Table

List of Tables

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

Oncolytics Biotech Inc, Deals By Therapy Area, 2012 to YTD 2018 10

Oncolytics Biotech Inc, Medical Devices Deals, 2012 to YTD 2018 11

Oncolytics Biotech Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12

Oncolytics Biotech to Raise up to USD26 Million in Private Placement of Shares 13

Oncolytics Biotech Enters into Agreement with SOLTI 14

Oncolytics Biotech Enters into Research Partnership with Keck School of Medicine of University of Southern California 15

Oncolytics Biotech Enters into Licensing Agreement with Adlai Nortye Biopharma 16

Oncolytics Biotech Raises USD8.9 Million in Public Offering of Share 17

Oncolytics Biotech Raises USD8.5 Million in Public Offering of Units 18

Oncolytics Biotech to Raise USD20 Million in Public Offering of Common Stock 19

Oncolytics Biotech Completes First Tranche Of Private Placement Of Shares For USD 1 Million 20

Oncolytics Biotech Completes Public Offering Of Common Stock For USD 32 Million 21

Oncolytics Biotech Completes Private Placement Of Shares For USD 21 Million 22

Oncolytics Biotech Inc, Key Competitors 24

Oncolytics Biotech Inc, Key Employees 25

Oncolytics Biotech Inc, Other Locations 26

Oncolytics Biotech Inc, Subsidiaries 26

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Oncolytics Biotech Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.